亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis

医学 彭布罗利珠单抗 阿替唑单抗 化疗 肿瘤科 危险系数 内科学 人口 荟萃分析 转移性尿路上皮癌 顺铂 免疫疗法 癌症 膀胱癌 尿路上皮癌 置信区间 环境卫生
作者
Alberto Martini,Daniele Raggi,Giuseppe Fallara,Luigi Nocera,Julianne G. Schultz,Federico Belladelli,Laura Marandino,Andrea Salonia,Alberto Briganti,Francesco Montorsi,Thomas Powles,Andrea Necchi
出处
期刊:Cancer Treatment Reviews [Elsevier BV]
卷期号:104: 102360-102360 被引量:24
标识
DOI:10.1016/j.ctrv.2022.102360
摘要

Pembrolizumab and atezolizumab have recently been approved for the first-line treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for cisplatin-based chemotherapy and whose tumors have high PD-L1 expression; however, the use of these immunotherapeutic agents relative to standard of care chemotherapy has ongoing concerns. The aim of this present study is to compare the effectiveness of single-agent immune-oncology (IO) compounds versus platinum-based chemotherapy in the first-line setting of aUC.A comprehensive search for phase III trials on IO versus chemotherapy was conducted in PubMed, EMBASE, Web of Science, and Scopus databases from 01/2016 to 05/2021. An algorithm to obtain survival data from published Kaplan-Meier curves was used to reconstruct overall survival (OS) data. After demonstrating violation of the proportional hazard assumption, we used the difference in restricted mean survival time (ΔRMST) to compare OS.OS data from 2,068 individuals from 3 phase III trials investigating the role of IO vs chemotherapy were reconciled. Overall, patients receiving IO [n = 1,013 (49%)] or chemotherapy [n = 1,055 (51%)] had similar OS with a 24-month ΔRMST of -0.4 (95% CI: -1.1, 0.4; p = 0.2) months. In the cisplatin-ineligible population, patients receiving IO [n = 509 (49%)] or chemotherapy [n = 530 (51%)] had similar OS with a 24-month ΔRMST of 0.1 (95% CI: -0.9, 1.2; p = 0.7) months. In the cisplatin-ineligible population with PD-L1-high tumors, patients receiving IO [n = 226 (50%)] or chemotherapy [n = 226 (50%)] had similar OS with a 24-month ΔRMST of 1.1 (95% CI: -0.5, 2.7; p = 0.1) months.We found no OS benefit for patients treated with first-line immune checkpoint inhibition compared to chemotherapy among the overall population, cisplatin-ineligible patients, and PD-L1-high patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开朗含海完成签到,获得积分10
3秒前
7秒前
在水一方的应助被mmyhn采纳,获得10
9秒前
科研通AI65的应助被hxjnx采纳,获得10
10秒前
sugar发布了新的文献求助10
10秒前
13秒前
虚心问旋完成签到,获得积分10
21秒前
23秒前
28秒前
29秒前
赘婿的应助被科盲TCB采纳,获得10
33秒前
睁眼睡大觉完成签到 ,获得积分10
35秒前
35秒前
灵竹完成签到,获得积分10
38秒前
39秒前
众里寻你呀完成签到 ,获得积分10
40秒前
43秒前
科盲TCB发布了新的文献求助10
46秒前
hxjnx发布了新的文献求助10
46秒前
桐桐的应助被FIGGIEKIO采纳,获得10
48秒前
58秒前
1分钟前
浩ovo完成签到,获得积分10
1分钟前
山豬完成签到,获得积分10
1分钟前
学术废物发布了新的文献求助10
1分钟前
1分钟前
快乐的文博完成签到,获得积分10
1分钟前
hxjnx完成签到,获得积分20
1分钟前
李ok发布了新的文献求助10
1分钟前
姍豬完成签到,获得积分10
1分钟前
哈哈完成签到 ,获得积分10
1分钟前
徐伟业完成签到 ,获得积分10
1分钟前
1分钟前
Ava的应助被风趣月亮采纳,获得30
1分钟前
1分钟前
1分钟前
luyiyi发布了新的文献求助20
1分钟前
碧蓝问玉完成签到,获得积分10
1分钟前
1分钟前
地尔硫卓发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195022
求助须知:如何正确求助?哪些是违规求助? 9580753
关于积分的说明 21872568
捐赠科研通 7794759
什么是DOI,文献DOI怎么找? 3437852
关于科研通互助平台的介绍 2561176
邀请新用户注册赠送积分活动 2484546